MEK inhibitors targeting the MAPK pathway are used in combination with BRAF inhibitors in melanoma, metastatic lung cancer, and metastatic anaplastic thyroid cancer when a BRAF V600E or V600K mutation is present. This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.